Q-omics provides the consensus-scored SNORD13E profile across patient tissues and cancer cell-line models. SNORD13E expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, SNORD13E is differentially expressed in 4, with the highest sampling consensus in KIRP. Additionally, SNORD13E RNA expression shows 11,755 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, KIRP, and UVM as cancer lineages where SNORD13E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORD13E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORD13E survival associations across molecular data types. SNORD13E RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORD13E RNA expression–survival associations across cancer types. High SNORD13E expression shows unfavorable associations in KICH, but favorable associations in SKCM, HNSC, LUAD, READ and COAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for SNORD13E RNA expression.
This table summarizes SNORD13E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SNORD13E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORD13E shows lower tumor expression in KIRP and BRCA and higher tumor expression in STAD and HNSC. The KIRP box plot shows higher SNORD13E RNA expression in normal versus tumor tissue (log2 FC = −0.360, t-test p = .031).
This table shows molecular features associated with SNORD13E in patient tissues and cancer cell lines. In patient samples, SNORD13E shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
